Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367627839> ?p ?o ?g. }
- W4367627839 endingPage "1568" @default.
- W4367627839 startingPage "1558" @default.
- W4367627839 abstract "Sarcopenia is characterized by a progressive decrease in skeletal muscle mass and function with age. Given that sarcopenia is associated with various metabolic disorders, effective metabolic biomarkers for its early detection are required. We aimed to investigate the metabolic biomarkers related to sarcopenia in elderly men and perform experimental studies using metabolomics.Plasma metabolites from 142 elderly men, comprising a sarcopenia group and an age-matched control group, were measured using global metabolome profiling. Muscle and plasma samples from an aging mouse model of sarcopenia, as well as cell media and cell lysates during myoblast differentiation, were analysed based on targeted metabolome profiling. Based on these experimental results, fatty acid amides were quantified from human plasma as well as human muscle tissues. The association of fatty acid amide levels with sarcopenia parameters was evaluated.Global metabolome profiling showed that fatty acid amide levels were significantly different in the plasma of elderly men with sarcopenia (all Ps < 0.01). Consistent with these results in human plasma, targeted metabolome profiling in an aging mouse model of sarcopenia showed decreased levels of fatty acid amides in plasma but not in muscle tissue. In addition, the levels of fatty acid amides increased in cell lysates during muscle cell differentiation. Targeted metabolome profiling in men showed decreased docosahexaenoic acid ethanolamide (DHA EA) levels in the plasma (P = 0.016) but not in the muscle of men with sarcopenia. DHA EA level was positively correlated with sarcopenia parameters such as skeletal muscle mass index (SMI) and handgrip strength (HGS) (P = 0.001, P = 0.001, respectively). The area under the receiver-operating characteristic curve (AUC) for DHA EA level ≤ 4.60 fmol/μL for sarcopenia was 0.618 (95% confidence interval [CI]: 0.532-0.698). DHA EA level ≤ 4.60 fmol/μL was associated with a significantly greater likelihood of sarcopenia (odds ratio [OR]: 2.11, 95% CI: 1.03-4.30), independent of HGS. The addition of DHA EA level to age and HGS significantly improved the AUC from 0.620 to 0.691 (P = 0.0497).Our study demonstrated that fatty acid amides are potential circulating biomarkers in elderly men with sarcopenia. DHA EA, in particular, strongly related to muscle mass and strength, can be a key metabolite to become a reliable metabolic biomarker for sarcopenia. Further research on fatty acid amides will provide insights into the metabolomic changes relevant to sarcopenia from an aging perspective." @default.
- W4367627839 created "2023-05-02" @default.
- W4367627839 creator A5006158337 @default.
- W4367627839 creator A5006710275 @default.
- W4367627839 creator A5008788138 @default.
- W4367627839 creator A5025828391 @default.
- W4367627839 creator A5029697536 @default.
- W4367627839 creator A5045318953 @default.
- W4367627839 creator A5057474625 @default.
- W4367627839 creator A5060201050 @default.
- W4367627839 creator A5063910036 @default.
- W4367627839 creator A5082648255 @default.
- W4367627839 creator A5085278233 @default.
- W4367627839 date "2023-05-01" @default.
- W4367627839 modified "2023-10-17" @default.
- W4367627839 title "Fatty acid amides as potential circulating biomarkers for sarcopenia" @default.
- W4367627839 cites W1904016752 @default.
- W4367627839 cites W1964097306 @default.
- W4367627839 cites W2000067605 @default.
- W4367627839 cites W2017018911 @default.
- W4367627839 cites W2048278414 @default.
- W4367627839 cites W2048654753 @default.
- W4367627839 cites W2094625212 @default.
- W4367627839 cites W2102902846 @default.
- W4367627839 cites W2106989260 @default.
- W4367627839 cites W2107549333 @default.
- W4367627839 cites W2110065044 @default.
- W4367627839 cites W2131620744 @default.
- W4367627839 cites W2134268004 @default.
- W4367627839 cites W2152817152 @default.
- W4367627839 cites W2170913141 @default.
- W4367627839 cites W2171004709 @default.
- W4367627839 cites W2188690658 @default.
- W4367627839 cites W2290280758 @default.
- W4367627839 cites W2321445261 @default.
- W4367627839 cites W2474070039 @default.
- W4367627839 cites W2531724552 @default.
- W4367627839 cites W2531807162 @default.
- W4367627839 cites W2625968983 @default.
- W4367627839 cites W2737796575 @default.
- W4367627839 cites W2800472367 @default.
- W4367627839 cites W2802842185 @default.
- W4367627839 cites W2804501047 @default.
- W4367627839 cites W2897513125 @default.
- W4367627839 cites W2969182133 @default.
- W4367627839 cites W2969918865 @default.
- W4367627839 cites W2975817808 @default.
- W4367627839 cites W3005437800 @default.
- W4367627839 cites W3022107726 @default.
- W4367627839 cites W3088165492 @default.
- W4367627839 cites W3096682085 @default.
- W4367627839 cites W3158552092 @default.
- W4367627839 cites W3198752567 @default.
- W4367627839 cites W3216171698 @default.
- W4367627839 cites W4200379278 @default.
- W4367627839 cites W4214841853 @default.
- W4367627839 cites W4367627839 @default.
- W4367627839 doi "https://doi.org/10.1002/jcsm.13244" @default.
- W4367627839 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37127296" @default.
- W4367627839 hasPublicationYear "2023" @default.
- W4367627839 type Work @default.
- W4367627839 citedByCount "2" @default.
- W4367627839 countsByYear W43676278392023 @default.
- W4367627839 crossrefType "journal-article" @default.
- W4367627839 hasAuthorship W4367627839A5006158337 @default.
- W4367627839 hasAuthorship W4367627839A5006710275 @default.
- W4367627839 hasAuthorship W4367627839A5008788138 @default.
- W4367627839 hasAuthorship W4367627839A5025828391 @default.
- W4367627839 hasAuthorship W4367627839A5029697536 @default.
- W4367627839 hasAuthorship W4367627839A5045318953 @default.
- W4367627839 hasAuthorship W4367627839A5057474625 @default.
- W4367627839 hasAuthorship W4367627839A5060201050 @default.
- W4367627839 hasAuthorship W4367627839A5063910036 @default.
- W4367627839 hasAuthorship W4367627839A5082648255 @default.
- W4367627839 hasAuthorship W4367627839A5085278233 @default.
- W4367627839 hasBestOaLocation W43676278391 @default.
- W4367627839 hasConcept C126322002 @default.
- W4367627839 hasConcept C134018914 @default.
- W4367627839 hasConcept C135870905 @default.
- W4367627839 hasConcept C21565614 @default.
- W4367627839 hasConcept C2776214593 @default.
- W4367627839 hasConcept C2777477808 @default.
- W4367627839 hasConcept C2779959927 @default.
- W4367627839 hasConcept C543025807 @default.
- W4367627839 hasConcept C55493867 @default.
- W4367627839 hasConcept C60644358 @default.
- W4367627839 hasConcept C71924100 @default.
- W4367627839 hasConcept C86803240 @default.
- W4367627839 hasConceptScore W4367627839C126322002 @default.
- W4367627839 hasConceptScore W4367627839C134018914 @default.
- W4367627839 hasConceptScore W4367627839C135870905 @default.
- W4367627839 hasConceptScore W4367627839C21565614 @default.
- W4367627839 hasConceptScore W4367627839C2776214593 @default.
- W4367627839 hasConceptScore W4367627839C2777477808 @default.
- W4367627839 hasConceptScore W4367627839C2779959927 @default.
- W4367627839 hasConceptScore W4367627839C543025807 @default.
- W4367627839 hasConceptScore W4367627839C55493867 @default.
- W4367627839 hasConceptScore W4367627839C60644358 @default.